Sugi Predict

Sugi Predict / Compounds / SCHEMBL172718

SCHEMBL172718

SCHEMBL172718

Cc1cc(-c2ccccn2)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 6/20 0.51
▸ HSD17B2 P37059 6/20 0.51
▸ HSD17B14 Q9BPX1 1/20 0.49
▸ ESR1 P03372 3/20 0.48
▸ CDC7 O00311 1/20 0.48
▸ PIM1 P11309 1/20 0.48
▸ CSNK2A2 P19784 1/20 0.48
▸ CLK1 P49759 1/20 0.48
▸ GSK3B P49841 1/20 0.48
▸ CSNK2B P67870 1/20 0.48
▸ CSNK2A1 P68400 1/20 0.48
▸ CSNK2A3 Q8NEV1 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RET P07949 1/20 0.47
▸ RIPK1 Q13546 1/20 0.47
▸ RIPK3 Q9Y572 1/20 0.47
▸ ESR2 Q92731 3/20 0.46
▸ LMNA P02545 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL17744696 0.98 HSD17B1 (0.50) HSD17B1HSD17B2HSD17B14ESR1CDC7
SCHEMBL23525612 0.86 RET (0.50) HSD17B14KDM4ENPC1RETRIPK1
SCHEMBL30610290 0.86 RET (0.50) HSD17B14KDM4ENPC1RETRIPK1
SCHEMBL7662434 0.83 KDM4E (0.56) KDM4ENPC1RETRIPK1RIPK3
SCHEMBL10756157 0.83 POLB (0.54) KDM4ENPC1LMNACYP1A2POLB
SCHEMBL8824445 0.81 KDM4E (0.55) KDM4ENPC1RETRIPK1RIPK3
Bromide SCHEMBL11334286 0.81 POLB (0.52) KDM4ENPC1LMNACYP1A2POLB
SCHEMBL16385167 0.79 HSD17B1 (0.52) HSD17B1HSD17B2ESR1ESR2TLR8
SCHEMBL16385302 0.79 CCR1 (0.55) HSD17B1HSD17B2HSD17B14CDC7PIM1
SCHEMBL6974543 0.79 KDM4E (0.56) KDM4ENPC1RETLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 — — EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 — — US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 — — US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 — — US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 — — US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 — — WO disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 — — US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 — — US disclosed
EP-1352650-B1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES INST MED MOLECULAR DESIGN INC (JP) 2012-03-07 — — EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 — — US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 — — US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 — — US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 — — EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 — — EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 — — US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 HSD17B1 231/4885HSD17B2 273/4885HSD17B14 586/4885
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 HSD17B1 1419/4885HSD17B2 2000/4885HSD17B14 3208/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR HSD17B1 275/4885HSD17B2 324/4885HSD17B14 686/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR HSD17B1 233/4885HSD17B2 293/4885HSD17B14 615/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA HSD17B1 714/4885HSD17B2 878/4885HSD17B14 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.